ABSTRACT
BACKGROUND: A feasibility version of the GlucoClear™ continuous glucose monitoring system (Edwards Lifesciences, Irvine, CA), the intravenous blood glucose (IVBG) system, developed to facilitate glycemic management, was evaluated. MATERIALS AND METHODS: Two pilot studies were conducted. Ten volunteers with diabetes (1,725 matched pairs) and 10 patients scheduled for intensive care unit (ICU) admission following surgery (1,393 matched pairs) were studied. The patients' blood glucose concentrations were monitored by the IVBG system every 5 min for up to 72 h. The accuracy of the IVBG system was calculated and compared with the Yellow Springs Instrument (YSI) (Yellows Springs, OH) and Radiometer (Copenhagen, Denmark) measurements to determine the percentage of matched pairs that met 15/20%, 10/15%, 12/12.5%, and 10/10% assessment criteria. Performance was calculated as the percentage of the total measurements that would have been displayed in an unblinded study. Adverse events were monitored. RESULTS: The accuracy of the IVBG system met the International Organization for Standardization ISO 15197 15/20% criterion (99.07% in volunteers, 99.43% in the ICU, and both vs. YSI) and the stricter 10/15% criterion (96.17% in volunteers, 96.77% in the ICU, and both vs. YSI) over the 72-h period and across a broad range of blood glucose concentrations. Performance was 89.97% in the ICU study. The adverse device effects included induration of the peripheral vein, mild bruising, and mild hematoma. In the volunteers, there were patency problems with six catheters. CONCLUSIONS: The IVBG system is safe, accurate, and reliable. This minimally invasive system was not affected by potentially interfering medications. Real-time measurements, alarms, and trends provided by the IVBG system might support glycemic control protocols and prevent glycemic events in critically ill patients.
Subject(s)
Blood Glucose/analysis , Diabetes Mellitus/blood , Hyperglycemia/diagnosis , Hypoglycemia/diagnosis , Monitoring, Physiologic/instrumentation , Point-of-Care Systems , Postoperative Complications/diagnosis , Adult , Belgium , Feasibility Studies , Follow-Up Studies , Humans , Intensive Care Units , Male , Materials Testing , Monitoring, Physiologic/adverse effects , Outpatient Clinics, Hospital , Pilot Projects , Postoperative Complications/blood , Practice Guidelines as Topic , Reproducibility of ResultsABSTRACT
The traditional intraoperative two-dimensional transesophageal echocardiography (2DTEE) has limitations in measuring left ventricular ejection fraction (LVEF) because measurements rely on geometric assumptions. The availability of online software and real time three-dimensional transesophageal echocardiography (RT3D-TEE) makes intraoperative LVEF measurements fast and easy. This is the first report of intraoperative measurement of LVEF and aortic valve area (AVA) by RT3-DTEE in a patient who received transcatheter-based transapical aortic valve implantation.
Subject(s)
Aortic Valve/diagnostic imaging , Echocardiography, Three-Dimensional , Echocardiography, Transesophageal , Heart Valve Prosthesis Implantation/adverse effects , Hemodynamics , Intraoperative Complications , Aged , Aortic Valve/pathology , Female , HumansABSTRACT
BACKGROUND: Recent advances in three-dimensional (3D) echocardiography allow to obtain real-time 3D transesophageal (RT3DTEE) images intraoperatively. METHODS: Preoperative transthoracic echocardiography (TTE) revealed: hypertrophic ventricular septum (TTE:19.3 mm), systolic anterior motion (SAM) not causing obstruction and malcoaptation of the anterior mitral valve leaflet (AMVL), and posterior mitral valve leaflet (PMVL) with severe mitral regurgitation. RESULTS: Intraoperative TEE with a x7-2t MATRIX-array transducer (Philips, Andover, MA, USA) with a transducer frequency of x7-2 t mHz, connected to a iE33 (Philips), shows us that the main mechanism and site of regurgitation was an AMVL cleft. We also measured a 24.3-mm thickness of the ventricular septum and analyzing the 3D full volume acquisition revealed that there was no SAM. CONCLUSION: Intraoperative RT3DTEE permitted comprehensive 3D viewing of the mitral valve revealing the mechanism of mitral valve regurgitation, SAM, and the exact width of the hypertrophic ventricular septum.
Subject(s)
Aortic Valve Insufficiency/surgery , Aortic Valve/surgery , Echocardiography, Transesophageal , Heart Valve Prosthesis , Thoracic Surgery/methods , Adult , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Aortic Valve Insufficiency/pathology , Computer Systems , Female , Heart Septum/diagnostic imaging , Humans , Hypertrophy, Left Ventricular/diagnostic imaging , Hypertrophy, Right Ventricular/diagnostic imaging , Intraoperative Period , Male , Mitral Valve/diagnostic imaging , Mitral Valve Insufficiency/diagnostic imaging , Predictive Value of TestsABSTRACT
Right atrial myxomas are uncommon heart tumors that can simulate nonspecific symptoms, such as fever, paroxysmal palpitations, chronic anemia, weight loss, and may escape timely diagnosis until the development of severe complications due to embolism. We present a patient with a history of palpitations. In search for the source of palpitations, a 2D transthoracic echocardiography was performed, showing a right atrial mass. Real time three-dimensional transesophageal echocardiography (RT3DTEE) was performed intraoperative and demonstrated very accurate information about the size and the morphology of the tumor. This is the first case report of a right atrial myxoma visualized intraoperatively by RT3DTEE.
